# A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors

> **NCT04009460** · PHASE1 · TERMINATED · sponsor: **Elpiscience Biopharma, Ltd.** · enrollment: 22 (actual)

## Conditions studied

- Solid Tumors
- Neoplasms
- Malignant Tumor

## Interventions

- **DRUG:** ES101

## Key facts

- **NCT ID:** NCT04009460
- **Lead sponsor:** Elpiscience Biopharma, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-28
- **Primary completion:** 2022-04-22
- **Final completion:** 2022-04-22
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Sponsor's clinical development strategy adjustment
- **Last updated:** 2022-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04009460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04009460, "A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04009460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*